Equipalazone Paste treatment of musculoskeletal disorders-Hyperdrug

Dosage and administration Each marked division (2 turns of the ring) is equivalent to 1 unit dose (ie 1g). Horses: 450 kg (1000 lbs) bodyweight. 2 unit doses twice on day one (equivalent to 8.8 mg/kg/day). I unit dose twice daily for four days (4.4 mg/kg/day) followed by one unit dose daily or on alternate days (2.2 mg/kg/day) sufficient to keep the animal comfortable. Ponies: 225 kg (500 lbs) bodyweight. 1 unit dose (4.4 mg/kg) on alternate days. Remove cap from nozzle, turn ring to required dosage and express as near to the back of the tongue as possible. Avoid the introduction of contamination during use. Any contents remaining later than 28 days after the date of first opening should be discarded. Dispose of any unused product or containers in accordance with guidance from your local waste regulation authority, e.g. the local regional office of the Environment Agency or SEPA. Adjust dose according to bodyweight. Discontinue treatment if no response is evident after four to five days treatment.

Contra-indications, warnings, etc Do not use in horses intended for human consumption. The product should be handled with care at all times to reduce the risk of accidental ingestion or skin contact. If accidental skin or eye contact occurs, the site should be washed immediately with water. If the product is ingested, see medical advice immediately and show the product packaging. Advice to doctors Gastric lavage (emesis in children) should be performed urgently. Charcoal haemoperfusion has also been shown to be beneficial.Treatment should then be administered symptomatically. The therapeutic index of phenylbutazone is low. Do not exceed the stated dose or the duration of treatment. Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects. Use in animals less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided. It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered. Use during pregnancy should be avoided whenever possible, particularly during the first trimester. Pharmaceutical precautions Replace cap after use. Store below 25°C. General precautions Keep out of the reach of children. For animal treatment only. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.

Legal category POM-V (previously POM). Packaging Quantities `Dial a dose' syringes containing 6 unit doses. Further information The clinical effect of phenylbutazone can be evident for at least 3 days following cessation of administration. This should be borne in mind when examining the horse for soundness. Some racing authorities (including the British Jockey Club) regard Phenylbutazone as a `prohibited substance' within their rules of racing. The Royal College of Veterinary Surgeons has given guidance to the veterinary profession regarding the elimination times of various anti-inflammatory drugs and they state `if a veterinarian recommends the discontinuance of any such drug not less than eight days before racing, he should be able to feel sure that he has catered for all but the most exceptional circumstances'. Marketing authorisation number Vm 01732/4081.

Equipalazone Paste (1 x 6 dose)